Cargando…
Acute retinal necrosis. Management and visual outcomes: a case series
BACKGROUND: The present study reports the functional and anatomical outcomes of eyes with acute retinal necrosis(ARN). METHODS: This is a retrospective case series conducted at a tertiary Eye Hospital from March 2015 to March 2020. Medical records of patients with clinical and laboratorial—Polymeras...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476592/ https://www.ncbi.nlm.nih.gov/pubmed/36109794 http://dx.doi.org/10.1186/s40942-022-00417-w |
_version_ | 1784790172635758592 |
---|---|
author | Mojarrad, Alireza Omidtabrizi, Arash Ansari Astaneh, Mohammadreza Bakhtiari, Elham Shiezadeh, Elham Hassani, Mohadeseh Hosseini, Seyedeh Maryam |
author_facet | Mojarrad, Alireza Omidtabrizi, Arash Ansari Astaneh, Mohammadreza Bakhtiari, Elham Shiezadeh, Elham Hassani, Mohadeseh Hosseini, Seyedeh Maryam |
author_sort | Mojarrad, Alireza |
collection | PubMed |
description | BACKGROUND: The present study reports the functional and anatomical outcomes of eyes with acute retinal necrosis(ARN). METHODS: This is a retrospective case series conducted at a tertiary Eye Hospital from March 2015 to March 2020. Medical records of patients with clinical and laboratorial—Polymerase Chain Reaction (PCR)—diagnosis of ARN were reviewed. To identify factors related to the outcomes of visual acuity(VA) and retinal detachment (RD) over time, Cox proportional hazards regression modeling and survival analyses were used. RESULTS: Twenty-three eyes of 23 patients (16 male, 7 female) were reviewed. Based on the PCR results, 16 cases (69.6%) had Varicella zoster virus, 3 cases (13%) had Cytomegalovirus, 1 patient (4.3%) had Herpes simplex virus associated ARN, and 1 case (4.3%) had negative PCR. The incident rate for ≥ 2-line VA gain was 0.28/eye-year (EY) (95% CI 0.21 ± 0.26) while the rate of severe vision loss was 0.09/eye-year (95% CI 0.05 ± 0.08). The RD development was observed at a rate of 0.43/eye-year (0.42 ± 0.02), which occurred in 9 eyes with a mean time of 100 days after the initial presentation of ARN. Patients’ age was the only factor associated with 2-line or more gain in VA over time with a hazard ratio of 0.921 (95% CI 0.854–0.993, P = 0.032). CONCLUSIONS: Generally, although being crucial, treatment is not highly effective in improvement of VA and decrease of RD development, as well as vision loss, in patients with ARN. However, treatment prevents fellow eye involvement efficiently. Younger age is associated with better response to treatment and more chance to achieve better VA. |
format | Online Article Text |
id | pubmed-9476592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94765922022-09-16 Acute retinal necrosis. Management and visual outcomes: a case series Mojarrad, Alireza Omidtabrizi, Arash Ansari Astaneh, Mohammadreza Bakhtiari, Elham Shiezadeh, Elham Hassani, Mohadeseh Hosseini, Seyedeh Maryam Int J Retina Vitreous Original Article BACKGROUND: The present study reports the functional and anatomical outcomes of eyes with acute retinal necrosis(ARN). METHODS: This is a retrospective case series conducted at a tertiary Eye Hospital from March 2015 to March 2020. Medical records of patients with clinical and laboratorial—Polymerase Chain Reaction (PCR)—diagnosis of ARN were reviewed. To identify factors related to the outcomes of visual acuity(VA) and retinal detachment (RD) over time, Cox proportional hazards regression modeling and survival analyses were used. RESULTS: Twenty-three eyes of 23 patients (16 male, 7 female) were reviewed. Based on the PCR results, 16 cases (69.6%) had Varicella zoster virus, 3 cases (13%) had Cytomegalovirus, 1 patient (4.3%) had Herpes simplex virus associated ARN, and 1 case (4.3%) had negative PCR. The incident rate for ≥ 2-line VA gain was 0.28/eye-year (EY) (95% CI 0.21 ± 0.26) while the rate of severe vision loss was 0.09/eye-year (95% CI 0.05 ± 0.08). The RD development was observed at a rate of 0.43/eye-year (0.42 ± 0.02), which occurred in 9 eyes with a mean time of 100 days after the initial presentation of ARN. Patients’ age was the only factor associated with 2-line or more gain in VA over time with a hazard ratio of 0.921 (95% CI 0.854–0.993, P = 0.032). CONCLUSIONS: Generally, although being crucial, treatment is not highly effective in improvement of VA and decrease of RD development, as well as vision loss, in patients with ARN. However, treatment prevents fellow eye involvement efficiently. Younger age is associated with better response to treatment and more chance to achieve better VA. BioMed Central 2022-09-15 /pmc/articles/PMC9476592/ /pubmed/36109794 http://dx.doi.org/10.1186/s40942-022-00417-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Article Mojarrad, Alireza Omidtabrizi, Arash Ansari Astaneh, Mohammadreza Bakhtiari, Elham Shiezadeh, Elham Hassani, Mohadeseh Hosseini, Seyedeh Maryam Acute retinal necrosis. Management and visual outcomes: a case series |
title | Acute retinal necrosis. Management and visual outcomes: a case series |
title_full | Acute retinal necrosis. Management and visual outcomes: a case series |
title_fullStr | Acute retinal necrosis. Management and visual outcomes: a case series |
title_full_unstemmed | Acute retinal necrosis. Management and visual outcomes: a case series |
title_short | Acute retinal necrosis. Management and visual outcomes: a case series |
title_sort | acute retinal necrosis. management and visual outcomes: a case series |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476592/ https://www.ncbi.nlm.nih.gov/pubmed/36109794 http://dx.doi.org/10.1186/s40942-022-00417-w |
work_keys_str_mv | AT mojarradalireza acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT omidtabriziarash acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT ansariastanehmohammadreza acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT bakhtiarielham acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT shiezadehelham acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT hassanimohadeseh acuteretinalnecrosismanagementandvisualoutcomesacaseseries AT hosseiniseyedehmaryam acuteretinalnecrosismanagementandvisualoutcomesacaseseries |